Type 2 diabetes and clinical trials

Diabetologist Sanjay Kalra puts the CAROLINA trial into historical context and considers the present-day implications for the use of DPP-4 inhibitors and sulfonylureas. 

Get more on: Sulfonylureas | DPP-4 inhibitors | Other diabetes medications

Uazman Alam and colleagues interrogate current evidence and real-world clinical scenarios to address whether enough is being done with the tools available to screen and diagnose diabetic neuropathy [read more].

Get more on: Diabetic neuropathy | Management of diabetic foot | Other diabetic complications

This post hoc analysis investigated the metabolic effects and baseline associations with bodyweight loss on coadministration of dapagliflozin and exenatide once weekly among adults with obesity and without diabetes [read more].
Pereira MJ et al. Diabetes Ther 2018. doi: 10.1007/s13300-018-0449-6

Get more on:  Medication | Obesity | Type 2 diabetes

This article evaluates the potential long-term effect of two different color indication methods for self-monitoring of blood glucose on metabolic parameters in insulin-treated type 2 diabetes [read more].
Nishimura A et al. Diabetes Ther 2018. doi: 10.1007/s13300-018-0457-6

Get more on:  Devices and technology | Type 2 diabetes

Editorial Board member John Wilding examines what real-world data means to today’s clinicians and presents his vision for the future of this type of evidence [read more].

Get more on: Type 2 diabetes | Clinical trials | Expert opinion

Board members Pamela Dyson and John Wilding talk about the fresh approach taken to the latest update of the Diabetes UK nutrition guidelines [listen to the podcast 9:43].

Get more on: Type 2 diabetes | Obesity | Diabetes prevention | Diet and nutritional management 

The drive to achieve lower HbA1c targets in older patients is not without concern or risk. Our UK Board address concerns highlighted by recent trials and discuss whether current guidelines do enough to mitigate the risks of overtreatment [read more].

Get more on: Medication | Older adults |  Type 2 diabetes

With the arrival of slow-release formulations of metformin and the relaxation of guidelines concerning its use in patients with kidney disease, Carol Wysham explains how the population of patients who might benefit from this medication has expanded [read more].

Get more on: Type 2 diabetes | Metformin | Medications | Expert opinion